Imatinib mesylate in the management of gastrointestinal stromal tumours (GIST)

被引：1
|
作者：
Kurteva G.P. [1 ]
Kurtev P.F. [1 ]
机构：
[1] National Center of Oncology, 1421 Lozenez, Sofia
来源：
memo - Magazine of European Medical Oncology | 2010年 / 3卷 / 2期
关键词：
c-Kit mutations; GIST; Glivec; Tyrosine kinase inhibitor;
D O I：
10.1007/s12254-010-0195-6
中图分类号：
学科分类号：
摘要：
Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy. The purpose of this manuscript is to present a comprehensive review about the treatment of this relatively new disease. A profound analysis is done concerning the effect of Imatinim mesilat (Glivec) as a therapeutic agent for the treatment of advanced GIST. The predictive role of the mutations in c-kit gene on the outcome of the GIST treatment with Glivec is recognized. In conclusion Glivec® is a highly specific target therapy, which completely has changed the paradigm for understanding cancer. This drug revolutionized the treatment of GIST, achieving three times longer survival comparing with the historical controls. © Springer-Verlag 2010.
引用
收藏
页码：49 / 52
页数：3
相关论文
共 50 条
  • [41] Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
    Zhou, Yongjian
    Chen, Jiabi
    Weng, Xiaoyuan
    Lin, Guosheng
    Huang, Zicheng
    Shu, Hanli
    ONCOLOGY LETTERS, 2018, 15 (05) : 7589 - 7594
  • [42] Gastric gastrointestinal stromal tumours (GIST): to needle or not?
    Smith, Matthew
    Chong, Andre
    Chin, Marcus
    Edmunds, Simon
    Raftopoulos, Spiro
    Ian, Yusoff
    Segarajasingam, Dev
    Siah, Chiang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 300 - 300
  • [43] Get the GIST? An overview of gastrointestinal stromal tumours
    G. A. Watson
    D. Kelly
    M. Melland-Smith
    J. Gleeson
    G. McEntee
    C. M. Kelly
    J. A. McCaffrey
    Irish Journal of Medical Science (1971 -), 2016, 185 : 319 - 326
  • [44] Get the GIST? An overview of gastrointestinal stromal tumours
    Watson, G. A.
    Kelly, D.
    Melland-Smith, M.
    Gleeson, J.
    McEntee, G.
    Kelly, C. M.
    McCaffrey, J. A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 (02) : 319 - 326
  • [45] Gastrointestinal stromal tumours (GIST): biology and treatment
    Judson, I
    ANNALS OF ONCOLOGY, 2002, 13 : 287 - 289
  • [46] MUTATIONAL ANALYSIS BEFORE AND AFTER NEOADJUVANT IMATINIB MESYLATE FOR LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMOURS
    Lemke, M.
    Ko, Y. H.
    Law, C.
    Haid, V.
    Rowsell, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 490 - 490
  • [47] Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall
    Pauwels, P
    Debiec-Rychter, M
    Stul, M
    De Wever, I
    Van Oosterom, AT
    Sciot, R
    HISTOPATHOLOGY, 2005, 47 (01) : 41 - 47
  • [48] Use of imatinib mesylate in gastrointestinal stromal tumours:: Pan-Birmingham Cancer Network Experience
    Wong, D. W. Y.
    Lupton, S. C.
    Bhatt, L.
    Gross, L.
    Taniere, P.
    Peake, D. R.
    Spooner, D.
    Geh, J. I.
    CLINICAL ONCOLOGY, 2008, 20 (07) : 517 - 522
  • [49] Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor
    Trent, Jonathan C.
    Dupart, Jheri
    Zhang, Wei
    CURRENT CANCER THERAPY REVIEWS, 2005, 1 (01) : 93 - 108
  • [50] Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
    Date, Ravindra S.
    Stylianides, Nicholas A.
    Pursnani, Kishore G.
    Ward, Jeremy B.
    Mughal, Muntzer M.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2008, 6 (1)
12345